Results 61 to 70 of about 94,511 (305)

Deficiency of DEK proto‐oncogene alleviates allergic rhinitis by inhibiting RhoA/Ezrin‐mediated mitochondrial fission

Animal Models and Experimental Medicine, EarlyView.
Schematic diagram of the mechanism of DEK regulating RhoA activation Ezrin. Upon house dust mite (HDM) stimulation, HDM‐specific immunoglobulin E (IgE) and inflammatory factors such as interleukin 4 (IL‐4), IL‐5, IL‐13, and eosinophils increased in the nasal mucosa.
Longzhu Dai, Yongde Jin, Jingmei Chai, Jianing Yang, Jiangang Wang, Mu Chen, Liangchang Li, Chongyang Wang, Guanghai Yan   +8 more
wiley   +1 more source

Guillain-Barré syndrome: celebrating a century

Arquivos de Neuro-Psiquiatria
A hundred years ago, Guillain, Barré and Strohl described a syndrome with a predominant motor acute or subacute polyneuritis, albumin-cytologic dissociation in the cerebrospinal fluid, and a benign course. Before them, many other authors, such as Landry,
Marcos R. G. de Freitas, Cecília M. Vidal, Marco Orsini   +2 more
doaj   +1 more source

Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability Associations

Annals of Neurology, EarlyView.
Objectives To examine volumetric magnetic resonance imaging (vMRI) in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), compared to multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and healthy controls (HC). Methods Standardized vMRI in MOGAD were compared to age, sex, and disease duration matched MS (5:1),
Amy Kunchok, Moein Amin, Tatchaporn Ongphichetmetha, Mengke Du, Robert Bermel, Tucker Harvey, Justin R. Abbatemarco, Stephen E. Jones, Jeffrey A. Cohen, Daniel Ontaneda, Kunio Nakamura   +10 more
wiley   +1 more source

Clinical Characteristics and Visual Outcomes of Pediatric Optic Neuritis: A Single Center Experience

Van Tıp Dergisi, 2022
INTRODUCTION: The aim of this study was to describe the clinical characteristics, visual outcomes of pediatric patients presenting with first-episode of optic neuritis.
Dilek Cebeci, Esra Gurkas, Zeynep Öztürk, Alev Güven, Zeynep Selen Karalok, Aydan Değerliyurt, Nefise Arıbaş Öz, İbrahim Halil Öncel, Serkan Özmen, Şükriye Yılmaz, Tülin Hakan Demirkan   +10 more
doaj   +1 more source

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica [PDF]

, 1887
Background: A polyspecific, intrathecal humoral immune response against neurotropic viruses such as measles, rubella and varicella zoster virus (MRZ reaction, MRZR) is present in 80--100% of patients with multiple sclerosis (MS), but has not to date been
Bergamaschi, R., Eichhorn, P., Franciotta, D., Jarius, S., Maurer, M., Petereit, H. F., Rauer, S., Tumani, H., Vincent, A., Voltz, R., Wandinger, K. P., Wick, M., Wildemann, B.   +12 more
core   +2 more sources

From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective The growing demand for personalized treatment in multiple sclerosis (MS) highlights the need for more precise biomarkers that can outperform magnetic resonance imaging and clinical assessment in patient stratification. Advances in multiplex proteomic technologies suggest that cerebrospinal fluid (CSF) analysis at MS onset may not only improve
Laura Ghezzi, Peter Kosa, Mark Greenwood, Enrique Alvarez, C.L. Freedman, Anne H. Cross, Francesca Pace, Mark S. Freedman, Joanna Kocot, Laura Piccio, Bibiana Bielekova   +10 more
wiley   +1 more source

Применение препарата Тригамма® в лечении заболеваний нервной системы

Архивъ внутренней медицины, 2011
The article discusses the questions of usage of the drug Trigamma® as a therapy of patients with lesions of the nervous system as well as some other diseases based on the experience of Russian and foreign experts. The advantages of the drug Trigamma® are
Е. А. Широков, А. А. Михайлов   +1 more
doaj   +1 more source

Hypertrophic Neuritis [PDF]

The Journal of Nervous and Mental Disease, 1920
n ...
Roussy, G., Cornil, L.
openaire   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [PDF]

, 2002
Background: In patients with isolated syndromes that are clinically suggestive of multiple sclerosis, such as optic neuritis or brain-stem or spinal cord syndromes, the presence of lesions as determined by T2-weighted magnetic resonance imaging (MRI) of ...
Brex, P.A., Ciccarelli, O., Miller, D.H., O'Riordan, J.I., Sailer, M., Thompson, A.J.   +5 more
core   +1 more source